Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial
As presented at the ESMO Congress 2026, in a randomized phase 2 trial evaluating an off-the-shelf lymph node-targeting peptide vaccine in patients with mutated KRAS pancreatic cancer within 6 months of standard curative intent therapy, the primary endpoint of disease-free survival was not met, but…